UNSPSC 51382703: Sulindac sodium

This classification denotes a cyclooxygenase inhibitor C20H16FO3S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NJV14I2XPC, chemically known as 1h-indene-3-acetic acid, 5-fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-, sodium salt (1:1), (1z)-, but more generally known as sulindac sodium, which bears US NIH Compound Identifier 23676448. European Medicines Agency schedules Sulindac sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04640MIG.

Most nations, for tariff and trade purposes, schedule sulindac sodium under HS 29309085 and SITC 51549. As of Q4 2014, SULINDAC SODIUM remains US FDA's Preferred Term for this commodity. SMILES: CC\1=C(C2CC(CCC2/C1=C\C3CCC(CC3)[S+](C)[O-])F)CC(=O)[O-].[NA+].

UNSPSC 51382703 Sulindac sodium is a Commodity code nominally for a nonsteroidal anti-inflammatory drug, but recent state and local solicitations posted under this code show minimal alignment with sulindac specifically. Instead, the opportunities reflect pharmaceutical procurement more broadly—naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products. The mismatch between the code's specific drug name and the actual scope of solicited work suggests the code may be tagged inconsistently or used as a placeholder within the pharmaceutical category. State and local buyers using this code include county health systems (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local government facilities across multiple jurisdictions including Oregon).

Recent activity spans Florida, Texas, and the Upper Midwest. Seminole County posted IFB60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually, due July 26, 2023, with quarterly deliveries to the Seminole County Community Health Building in Sanford and potential FEMA funding. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Department of Administration's Office of State Procurement, administering the MMCAP cooperative, released an RFP (S1070000015802) in January 2026 for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, requiring products available by May 15, 2026 and effective July 1, 2026, with pricing evaluation weighted 75 percent on competitiveness and mandatory relationships with AmerisourceBergen Drug Corporation, Cardinal Health, or Morris & Dickson wholesalers. Vendors pursuing this code should verify actual drug or product scope in the full solicitation before bidding.